Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07285304
PHASE3
A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Sponsor: Taisho Pharmaceutical Co., Ltd.
View on ClinicalTrials.gov
Summary
A clinical study to evaluate the long-term safety and efficacy of TS-172 in hyperphosphatemia patients on hemodialysis.
Official title: A Phase 3 Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2025-12-01
Completion Date
2027-07-31
Last Updated
2025-12-16
Healthy Volunteers
No
Interventions
DRUG
TS-172
oral administration of TS-172 20\~60 mg/day
Locations (1)
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan